Inclusion Criteria:

- Written Informed Consent obtained and documented according to national/local
regulations prior to any study-specific procedure.

- Males and females aged ≥18-85 years at the time of signing the informed consent
form.

- Patients with symptoms and signs of SARS-CoV-2 infection according to the World
Health Organization (WHO) case definition. Symptoms must include shortness of
breath, with an onset which occurred ≤ 10 days before admission, and the COVID-19
diagnosis must be confirmed by laboratory testing (PCR-positive). In addition,
moderately impaired oxygenation as demonstrated by oxygen saturation ≤ 93% but ≥ 87%
on room air, or requiring 1-5 L/min of oxygen to obtain an oxygen saturation of ≥
92%, and at least one of the following laboratory values:

(A) Ferritin: > 300 ng/mL for men and > 150 ng/mL for women. (B) C-reactive protein
(CRP): ≥ 10 mg/L. (C) D-dimer elevated above the age-adjusted lower limit: (i) ≤ 50
years; < 0.5 mg/L FEU (Fibrinogen Equivalent Units). (ii) > 50 years; age-related,
calculated as follows: 0.5 mg/L FEU + 0.01 mg/L FEU for every year over 50 (i.e., one who
is 70 years old has thus a reference limit of < 0.7 mg/L FEU; one who is 90 years old has
a reference limit of < 0.9 mg/L FEU).

- Able to swallow capsules

- Male subject must be willing to use condoms with spermicide, and if he has a fertile
partner, she must use contraceptive methods with a failure rate of < 1% to prevent
pregnancy. Male subjects must also refrain from donating sperm from the first dose
until three months after dosing with investigational product (IP). Female subjects
must be post-menopausal or use contraceptive methods with a failure rate of < 1% to
prevent pregnancy.

- Willingness and ability to comply with study procedures, visit schedules, study
restrictions and requirements.

Exclusion Criteria:

- Patient not committed to aggressive management. For example, the subject, the
subject's family or primary physician are unwilling to accept that the subject is
placed on mechanical ventilation; or in the case of an advanced directive to
withhold life support, with the exception of cardiopulmonary resuscitation.

- A suspected, active bacterial, fungal, viral, or other infection (besides COVID 19).

- Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) > 2 times the
upper limit of normal (ULN) detected at screening (per local lab) or suspected liver
disease.

- Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the
last 6 weeks, or decompensated congestive heart failure.

- Any condition for which, in the opinion of the investigator, participation would not
be in the best interest of the participant (e.g., compromise the well-being) or that
could prevent, limit, or confound the protocol-specified assessments.

- Clinically verified pulmonary embolism

- Chronic use of oral corticosteroids for treatment of inflammatory disease

- Use of strong CYP3A4 inhibitors (e.g., azoleantifungals, macrolide antibiotics,
protease inhibitors) or inducers (e.g., rifabutin and rifampicin) and drugs
sensitive to CYP3A4 inhibition (e.g., benzodiazepines, certain statins [lovastatin
and simvastatin], certain P2Y12 inhibitors [ticagrelor and clopidogrel]).

- Participation in another pharmaceutical clinical study.

- Subject who has received any investigational drug within the last 3 months before
administration of the investigational medicinal product (IMP).

- Severe COVID-19 at randomization: requiring non-invasive or invasive mechanical
ventilation or Intensive Care Unit (ICU) admission for any other cause than
respiratory support.

- Patients judged not to be suitable for non-invasive monitoring of oxygen saturation
because of impaired peripheral circulation or for other reasons.

- Active malignancy with or without treatment, except local basal cell carcinoma.